TransMedics Group Inc
$ 137.78
2.32%
24 Feb - close price
- Market Cap 4,601,572,000 USD
- Current Price $ 137.78
- High / Low $ 138.72 / 130.10
- Stock P/E 53.01
- Book Value 10.40
- EPS 2.54
- Next Earning Report 2026-02-24
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.32 %
- 52 Week High 156.00
- 52 Week Low 62.07
About
TransMedics Group, Inc., a commercial-stage medical technology company, is dedicated to transforming organ transplant therapy for patients with end-stage organ failure in the United States and internationally. The company is headquartered in Andover, Massachusetts.
Analyst Target Price
$144.20
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-24 | 2025-10-29 | 2025-07-29 | 2025-04-28 | 2025-02-24 | 2024-10-28 | 2024-07-31 | 2024-04-30 | 2024-02-26 | 2023-11-06 | 2023-08-03 | 2023-05-01 |
| Reported EPS | 0 | 0.66 | 0.92 | 0.7 | 0.19 | 0.12 | 0.35 | 0.35 | 0.12 | -0.78 | -0.03 | -0.08 |
| Estimated EPS | 0.3904 | 0.36 | 0.4453 | 0.2413 | 0.22 | 0.29 | 0.21 | -0.04 | -0.03 | -0.16 | -0.13 | -0.25 |
| Surprise | -0.3904 | 0.3 | 0.4747 | 0.4587 | -0.03 | -0.17 | 0.14 | 0.39 | 0.15 | -0.62 | 0.1 | 0.17 |
| Surprise Percentage | -100% | 83.3333% | 106.6023% | 190.0953% | -13.6364% | -58.6207% | 66.6667% | 975% | 500% | -387.5% | 76.9231% | 68% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.41 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TMDX
2026-02-24 21:54:34
TransMedics Group (NASDAQ:TMDX) announced its quarterly earnings, reporting an EPS of $2.62, significantly surpassing the consensus estimate of $0.41 by $2.21. The company also exceeded revenue expectations, bringing in $160.76 million against an anticipated $155.28 million. Following the strong results, TMDX stock traded up to $137.78, and analysts maintained a "Moderate Buy" consensus rating with an average price target of $144.25.
2026-02-24 21:54:34
TransMedics Group Inc. reported strong fourth-quarter financial results, surpassing Wall Street expectations. The company achieved $105.4 million in earnings with adjusted earnings of 57 cents per share, and revenue reached $160.8 million. For the full year, TransMedics posted a profit of $190.3 million on revenues of $605.5 million and projects future annual revenue between $727 million and $757 million.
2026-02-24 20:54:34
TransMedics Group, Inc. (TMDX) announced its Q4 2025 revenue reached $160.8 million, surpassing the FactSet estimate of $155.4 million. This financial update was released on February 24, 2026, and also noted a rise in the company's Q4 net income, leading to an after-hours gain in shares.
2026-02-24 19:30:00
TransMedics (TMDX) reported strong Q4 earnings, beating analyst estimates with $0.57 per share compared to a consensus of $0.41, and revenues of $160.76 million, surpassing the $155.91 million estimate. The company has consistently exceeded EPS expectations over the past four quarters. Despite outperforming the market year-to-date, TransMedics currently holds a Zacks Rank #3 (Hold) due to mixed estimate revisions ahead of the earnings release.
2026-02-23 23:38:37
TransMedics Group (TMDX) is anticipated to report a 27.4% increase in revenue for Q4, with EPS estimates rising and revenue estimates falling, suggesting cautious optimism. The medical technology company, valued at $4.6 billion, is known for its Organ Care System (OCS) and displays strong financial health despite insider selling and high stock volatility. Investors should weigh the company's robust growth and strong balance sheet against its premium valuation and market risks.
2026-02-23 22:31:38
TransMedics Group (TMDX) recently secured full FDA approval for its Next-Generation OCS ENHANCE Heart trial IDE, following previous approvals for DENOVO Lung IDE and a conditional ENHANCE Heart IDE. This approval is significant as the ENHANCE Heart study aims to prolong heart perfusion in brain-death donations, potentially revolutionizing heart transplantation. The company's investment narrative now heavily relies on the successful commercial rollout of these advanced platforms and its ability to manage regulatory challenges and operational scaling.
